Pulmonary exacerbations in cystic fibrosis: Young children with characteristic signs and symptoms

Pediatric Pulmonology

Volumn 48, Issue 7, 2013, Pages 649-657

  Regelmann, Warren E ^a   Schechter, Michael S ^b   Wagener, Jeffrey S ^c   Morgan, Wayne J ^d   Pasta, David J ^e   Elkin, Eric P ^e   Konstan, Michael W ^f  

^a UNIVERSITY OF MINNESOTA   (United States)

^b EMORY UNIVERSITY   (United States)

^c UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

^e ICON Late Phase and Outcomes Research   (United States)

^f CASE WESTERN RESERVE UNIVERSITY   (United States)

Author keywords

cough; crackles; cystic fibrosis; sputum; weight decline

Indexed keywords

QUINOLONE DERIVATIVE;

ABNORMAL RESPIRATORY SOUND; ANTIBIOTIC THERAPY; ARTICLE; CHILD; CHILD CARE; CHILD HOSPITALIZATION; COUGHING; DISEASE EXACERBATION; FEMALE; FOLLOW UP; FORCED EXPIRATORY VOLUME; HUMAN; LONGITUDINAL STUDY; LUNG CYSTIC FIBROSIS; LUNG FUNCTION; MAJOR CLINICAL STUDY; MALE; NUTRITIONAL STATUS; OBSERVATIONAL STUDY; PHYSICIAN; PRESCHOOL CHILD; PRESCRIPTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; PSEUDOMONAS INFECTION; RALE; RESPIRATORY TRACT DISEASE; SPUTUM; TREATMENT DURATION; WHEEZING;

ANTI-BACTERIAL AGENTS; CHILD, PRESCHOOL; COHORT STUDIES; COUGH; CYSTIC FIBROSIS; DISEASE PROGRESSION; FEMALE; HUMANS; INFANT; LONGITUDINAL STUDIES; MALE; PROSPECTIVE STUDIES; RESPIRATORY SOUNDS; RESPIRATORY TRACT INFECTIONS; SPUTUM; WEIGHT LOSS;

EID: 84879417125     PISSN: 87556863     EISSN: 10990496     Source Type: Journal    
DOI: 10.1002/ppul.22658     Document Type: Article

References (11)

1. Fuchs HJ, Borowitz DS, Christiansen DH, Morris EM, Nash ML, Ramsey BW, Rosenstein BJ, Smith AL, Wohl ME,. Effect of aerosolized recombinant human DNase on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis. The Pulmozyme Study Group. N Engl J Med 1994; 331: 637-642.
2. Goss CH, Burns JL,. Exacerbations in cystic fibrosis. 1: Epidemiology and pathogenesis. Thorax 2007; 62: 360-367.
3. Marshall BC,. Pulmonary exacerbations in cystic fibrosis: it's time to be explicit ! Am J Respir Crit Care Med 2004; 169: 781-782.
4. Rosenfeld M,. An overview of endpoints for cystic fibrosis clinical trials: one size does not fit all. Proc Am Thorac Soc 2007; 4: 299-301.
5. Morgan WJ, Butler SM, Johnson CA, Colin AA, FitzSimmons SC, Geller DE, Konstan MW, Light MJ, Rabin HR, Regelmann WE, Schidlow DV, Stokes DC, Wohl ME, Kaplowitz H, Wyatt MM, Stryker S,. Epidemiologic study of cystic fibrosis: design and implementation of a prospective, multicenter, observational study of patients with cystic fibrosis in the U.S. and Canada. Pediatr Pulmonol 1999; 28: 231-241.
6. Rabin HR, Butler SM, Wohl MEB, Geller DE, Colin AA, Schidlow DV, Johnson CA, Konstan MW, Regelmann WE, Epidemiologic Study of Cystic Fibrosis. Pulmonary exacerbations in cystic fibrosis: clinical signs and symptoms associated with antibiotic interventions. Pediatr Pulmonol 2004; 37: 400-406.
7. Rosenfeld M, Emerson J, Williams-Warren J, Pepe M, Smith A, Montgomery AB, Ramsey B,. Defining a pulmonary exacerbation in cystic fibrosis. J Pediatr 2001; 139: 359-365.
8. Rothman KJ, Wentworth CE, III, Mortality of cystic fibrosis patients treated with tobramycin solution for inhalation. Epidemiology 2003; 14: 55-59.
9. Johnson C, Butler SM, Konstan MW, Morgan W, Wohl ME,. Factors influencing outcomes in cystic fibrosis: a center-based analysis. Chest 2003; 123: 20-27.
10. Ramsey BW, Pepe MS, Quan JM, Otto KL, Montgomery AB, Williams-Warren J, Vasiljev KM, Borowitz D, Bowman CM, Marshall BC, Marshall S, Smith AL,. Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. Cystic Fibrosis Inhaled Tobramycin Study Group. N Engl J Med 1999; 340: 23-30.
11. Regelmann WE, Elliott GR, Warwick WJ, Clawson CC,. Reduction of sputum Pseudomonas aeruginosa density by antibiotics improves lung function in cystic fibrosis more than do bronchodilators and chest physiotherapy alone. Am Rev Respir Dis 1990; 141 (4 Pt 1): 914-921.